Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study.

Saved in:

Bibliographic Details
Title:	Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study.
Authors:	Schrader, E., Meier, B., Brattström, A.
Source:	Human Psychopharmacology: Clinical & Experimental. Apr98, Vol. 13 Issue 3, p163-169. 7p. 5 Charts, 2 Graphs.
Subjects:	Hypericum, Mental depression, Psychiatric drugs, Herbal medicine, Psychopharmacology
Abstract:	A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the efficacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild–moderate depression (ICD-10; F 32·0 mild; F 32·1 moderate). Patients on active medication received 250 mg extract tablets twice daily, corresponding to 1 mg hypericin daily, for 6 weeks. The primary efficacy variable was the 21 item Hamilton Depression Scale (HAMD); secondary variables were the risk-benefit Clinical Global Impression (CGI) scales I–III and a validated patient self-assessment on a Visual Analogue Scale (VAS). 162 patients entered the trial. 159 patients (80 on active medication) were evaluated in an intention-to-treat analysis; 136 patients (66 on active medication) in a protocol-compliant analysis. Patients in the two treatment groups did not differ with respect to the distribution of age, gender, weight and height. Based on differences in HAMD scores (p <0·001), both the intention-to-treat and protocol-compliant analyses demonstrate that ZE117 is clinically effective in the treatment of patients with mild to moderate depression following 6 weeks' treatment. Using the criteria of ≥50% reduction in HAMD score from baseline and/or an actual HAMD score ≤10 as evidence of a clinically relevant response, 56% patients treated with ZE117 were classified as responders, compared with 15% patients on placebo. The secondary efficacy variables data confirmed these findings. Compliance was high; using electronic devices within the medication containers, a therapeutic coverage of 81·7% was found. This was probably due, in part, to the low number of adverse events reported (11 total, 5 placebo, 6 active), the majority of which were transient, self-limiting and, in the case of active treatment, mostly non-specific gastrointestinal complaints. These results demonstrate that hypericum (ZE117) provides a safe and effective treatment for patients with mild to moderate depression. The good tolerability profile contributes to the high observed compliance, possibly conferring a clinical advantage in achieving efficacy over other antidepressants with less favourable side effect profiles. © 1998 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
	Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Psychology and Behavioral Sciences Collection

Description
Abstract:	A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the efficacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild–moderate depression (ICD-10; F 32·0 mild; F 32·1 moderate). Patients on active medication received 250 mg extract tablets twice daily, corresponding to 1 mg hypericin daily, for 6 weeks. The primary efficacy variable was the 21 item Hamilton Depression Scale (HAMD); secondary variables were the risk-benefit Clinical Global Impression (CGI) scales I–III and a validated patient self-assessment on a Visual Analogue Scale (VAS). 162 patients entered the trial. 159 patients (80 on active medication) were evaluated in an intention-to-treat analysis; 136 patients (66 on active medication) in a protocol-compliant analysis. Patients in the two treatment groups did not differ with respect to the distribution of age, gender, weight and height. Based on differences in HAMD scores (p <0·001), both the intention-to-treat and protocol-compliant analyses demonstrate that ZE117 is clinically effective in the treatment of patients with mild to moderate depression following 6 weeks' treatment. Using the criteria of ≥50% reduction in HAMD score from baseline and/or an actual HAMD score ≤10 as evidence of a clinically relevant response, 56% patients treated with ZE117 were classified as responders, compared with 15% patients on placebo. The secondary efficacy variables data confirmed these findings. Compliance was high; using electronic devices within the medication containers, a therapeutic coverage of 81·7% was found. This was probably due, in part, to the low number of adverse events reported (11 total, 5 placebo, 6 active), the majority of which were transient, self-limiting and, in the case of active treatment, mostly non-specific gastrointestinal complaints. These results demonstrate that hypericum (ZE117) provides a safe and effective treatment for patients with mild to moderate depression. The good tolerability profile contributes to the high observed compliance, possibly conferring a clinical advantage in achieving efficacy over other antidepressants with less favourable side effect profiles. © 1998 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
ISSN:	08856222
DOI:	10.1002/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.0.CO;2-I